Liquidia Corporation (NASDAQ:LQDA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Liquidia Corporation (NASDAQ:LQDAGet Free Report) have received a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and three have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $68.8750.

A number of research analysts have issued reports on the stock. Wall Street Zen downgraded shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Raymond James Financial reissued a “strong-buy” rating and set a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. HC Wainwright increased their price objective on shares of Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a report on Friday, June 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research note on Monday, May 11th.

Read Our Latest Stock Report on Liquidia

Insider Activity at Liquidia

In other news, insider Jason Adair sold 7,863 shares of the stock in a transaction on Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $562,283.13. Following the transaction, the insider owned 217,126 shares of the company’s stock, valued at $15,526,680.26. This represents a 3.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Kaseta sold 20,430 shares of the firm’s stock in a transaction on Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $1,460,949.30. Following the completion of the transaction, the chief financial officer owned 345,805 shares in the company, valued at $24,728,515.55. This represents a 5.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 2,022,134 shares of company stock worth $129,579,224. 25.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia during the 4th quarter worth about $25,000. NewEdge Advisors LLC acquired a new stake in shares of Liquidia in the 2nd quarter valued at approximately $25,000. FNY Investment Advisers LLC acquired a new stake in shares of Liquidia in the 3rd quarter valued at approximately $34,000. Covestor Ltd boosted its stake in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Liquidia by 281.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after acquiring an additional 4,927 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Trading Up 4.9%

LQDA stock opened at $80.89 on Wednesday. The company has a market cap of $7.19 billion, a P/E ratio of 577.83 and a beta of 0.55. Liquidia has a twelve month low of $15.12 and a twelve month high of $82.96. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The business has a fifty day moving average of $69.45 and a 200-day moving average of $49.05.

Liquidia (NASDAQ:LQDAGet Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business’s quarterly revenue was up 4187.1% on a year-over-year basis. As a group, equities research analysts expect that Liquidia will post 3.02 EPS for the current year.

Liquidia Company Profile

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

Featured Articles

Analyst Recommendations for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.